Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'

Pink Sheet’s Drug Review Profile looks at US FDA clinical memos opposing approval of Sarepta's Duchenne muscular dystrophy drug eteplirsen, revealing challenges patient advocates and agency face in transforming patient experiences into hard data that can be used for approvals.

Patient advocates played a very visible role in FDA's review of Sarepta Therapeutics Inc.'s Exondys 51 (eteplirsen) for Duchenne muscular dystrophy, but agency documents show just how difficult it can be for patient testimonials and caregiver surveys to sway FDA scientific staff when they believe the underlying clinical trial data fall short.

Agency reviewers could not reconcile what they saw as a disconnect between the clinical trial participants' experiences on eteplirsen versus...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Review Profiles

Akebia’s Vafseo: Japanese Postmarketing Data, Narrowed Indication Eased Liver Toxicity Worries

 
• By 

The Pink Sheet Drug Review Profile explores the US FDA’s approval of vadadustat to treat anemia in chronic kidney disease patients on dialysis. A complete response letter cited the risk of drug-induced liver injury, but postmarketing data from Japan reassured reviewers.

Vafseo Chronology: Complete Response Letter, Dispute Resolution And A Second-Cycle Approval

 
• By 

The Pink Sheet’s Drug Review Profile looks at the timeline behind the development and US FDA approval of Akebia’s Vafseo, a treatment for anemia in chronic kidney disease patients on dialysis.

The Next 340B Battle: Discount Duplication With Medicare Negotiated Prices

 
• By 

Manufacturers likely will have to determine when to provide a 340B discount on a drug assigned a Medicare negotiated price under CMS guidance. PhRMA anticipates the job will not be easy.

More from Product Reviews

data

New EU Filings

 
• By 

<p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

data

EU CHMP Opinions And MAA Updates

 
• By 

<p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

EU Biosimilar Filings, Opinions And Approvals

 
• By 

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>